Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents
Executive Summary
Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.
You may also be interested in...
FTC Competition Hearings: PhRMA, Former Rep. Waxman Advocate Focus On PBMs
FTC is assessing possible changes to competition and consumer protection enforcement law and policy, with a hearing on Innovation and IP Policy set for Oct. 23-24.
Sen. Hatch, Biopharma Industry Champion, Ready To Hang Up His Gloves
Hatch had a hand in major bipartisan legislation creating markets for generic drugs, orphan drugs, biosimilars, and dietary supplements.
Sen. Hatch, Biopharma Industry Champion, Ready To Hang Up His Gloves
Hatch had a hand in major bipartisan legislation creating markets for generic drugs, orphan drugs, biosimilars, and dietary supplements.